Generic Semaglutide Canada: Sandoz Copy of Ozempic Approved

Sandoz said on Sept. 18, 2026 that Health Canada has granted marketing authorization for Sandoz Semaglutide, a generic version of Novo Nordisk’s Ozempic, for the once-weekly treatment of adults with type 2 diabetes. Health Canada’s own Notice of Compliance record dates the decision to Sept. 16. The product is authorized — it is not on sale, and it is not the first generic of its kind in Canada.

What Health Canada authorized

The regulator’s records carry the decision, and they are more specific than the announcement. The Notice of Compliance is numbered 38299 and dated 2026-09-16, issued to Sandoz Canada Incorporated as an Abbreviated New Drug Submission, submission class “Labelling Only”. The Canadian reference product named in that record is OZEMPIC — the regulator’s own description of what this product is a copy of.

Two DINs sit under the authorization: 02571501, a multidose prefilled pen dispensing 0.25 mg or 0.5 mg doses, and 02571528, dispensing 1 mg doses. Both are 1.34 mg/mL semaglutide for subcutaneous injection, prescription status, ATC code A10BJ06. The Drug Product Database entry shows status “Approved” with a status date of 2026-09-16 and no original market date, which is the database’s way of recording a product that has not yet been sold.

Sandoz’s own framing is unambiguous: “Health Canada has granted marketing authorisation for Sandoz Semaglutide (semaglutide), a GLP-1 receptor agonist injection and a generic version of Ozempic.” The company said that in its global release on Sept. 18, and its Canadian arm used the same language in a release of its own the same day.

One field in the NOC record deserves care: the reason-for-submission reads “Administrative: Licensing Agreement between two manufacturers”. That is a record field, and the record names nobody — it does not identify a licensor, and it should not be read as one.

The indication is type 2 diabetes, not obesity

This is the detail that decides what the news does and does not mean. Sandoz’s own summary of the approval reads: “Semaglutide has been approved in Canada for once-weekly administration as a subcutaneous injection in adult patients with type-2 diabetes mellitus to improve glycaemic control.”

The fuller indication text in the same release begins “Sandoz Semaglutide is indicated for the once-weekly treatment of adult patients with type-2 diabetes to improve glycaemic control, in combination with:” and then lists combination regimens built around metformin, a sulfonylurea, an SGLT2 inhibitor and basal insulin, adding each step when diet, exercise and the previous therapy do not achieve adequate glycaemic control. There is no weight-management indication anywhere in it.

Health Canada has not published a product monograph for these DINs yet — the Drug Product Database page says “Electronic product monograph is not available” — so that wording is Sandoz’s, not regulator label text. It matches the reference label exactly: the OZEMPIC product monograph Health Canada hosts reads “OZEMPIC® is indicated for the once-weekly treatment of adult patients with type 2 diabetes to improve glycemic control, in combination with:” and the word “obesity” appears zero times across its 92-page monograph.

Canada’s obesity generic is a separate authorization on a separate reference product. Health Canada authorized a generic semaglutide injection for weight loss on June 29, 2026: Apotex’s Sevmia, a generic of Wegovy, indicated for patients 12 and over as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management. Nothing in the Sandoz decision extends to that use.

Sandoz’s is the last of five, not the first

Health Canada’s Notice of Compliance extract lists five authorizations whose Canadian reference product is OZEMPIC, and Sandoz’s is the most recent:

• Dr. Reddy’s Laboratories — NOC 37419, 2026-04-28. Health Canada’s release that day called it “the first generic semaglutide authorized by Health Canada, and the first to be approved in the G7.”
• Apotex Inc. — NOC 37448, 2026-05-01.
• Aspen Pharmacare Canada — NOC 37928, 2026-07-17, and NOC 38165, 2026-08-25.
• Sandoz Canada — NOC 38299, 2026-09-16.

The market status behind those dates matters too: the Drug Product Database shows Dr. Reddy’s semaglutide as Marketed since 2026-05-06 and Apotex’s since 2026-05-14, so a generic Ozempic has been dispensed in Canada since May. Sandoz’s release makes no first-claim of its own — the phrases “first generic” and “first in Canada” do not appear in it at all.

Authorized is not launched

Sandoz Canada is explicit that the authorization is a regulatory milestone, not a shipment: “Following Health Canada’s regulatory approval, Sandoz Canada is taking the necessary steps to prepare for the future commercialization of Pr Sandoz ® Semaglutide.” The Canadian release gives no launch date, and neither does the global one.

The parent company’s guidance points the same way: “The approval has no impact on Sandoz financial guidance for 2026 and the Company foresees no material contribution this year from any potential launches of generic semaglutide.” Nothing in the public record gives a Canadian retail price or a reimbursement decision for this product, so no figure circulating as a Canadian Ozempic price can be sourced to this authorization.

What generic entry usually does to price

Generic entry has historically pushed the price paid for a brand molecule down, and the more suppliers that actually ship, the larger and faster that move tends to be. That is an expectation built from how generic markets have behaved over decades, not a prediction about this product or a date by which anything changes.

The pace is set by things an authorization does not touch: provincial formulary listings and reimbursement rules, substitution and dispensing rules, where each manufacturer prices its own product, and how many of the five authorized suppliers actually commercialize. On that last point, Sandoz’s own guidance is the counterweight to a price-collapse story — the company says it expects no material generic contribution this year.

Sandoz also frames the size of what is being contested. Its release says “The regulatory approval comes in a GLP-1 market worth an estimated USD 2.6 billion”, with a footnote reading “Data on file. Based on full year 2025 IQVIA MAT data”, and a related bullet citing “close to 12 million semaglutide injection pens issued annually” in Canada. That market figure is Sandoz’s own estimate on data the company does not publish; it cannot be checked against IQVIA from outside, and it is not a Health Canada number. Treat it as a vendor estimate and attribute it accordingly.

For the US picture — where list prices, insurance coverage and telehealth plan pricing are set by an entirely different set of forces — see our 2026 GLP-1 pricing guide.

What this does not change

• Obesity indications. They are separate authorizations on separate reference products, as above. A generic of Ozempic is not a generic of Wegovy.
• The United States. No US generic semaglutide authorization is asserted here, and this decision says nothing about US availability or US pricing. What exists in the US is a different conversation: the Medicare GLP-1 Bridge program on the coverage side, and active litigation over compounded semaglutide on the supply side (Fifth Circuit ruling).
• Unapproved supply. This authorization concerns a licensed prescription medicine in Canada. It does not change the regulatory position of compounded or research-chemical semaglutide sold without approval in the US or elsewhere.
• The gray-market premium. Cheaper authorized supply in one country is one reason patients look abroad, but nothing announced here sets a price, so no premium can be calculated from it yet.
• Addiction and psychiatric use. GLP-1s for addiction are a separate, unapproved question: no agent in this class is approved to treat alcohol use disorder or depression, and the Phase 3 programs testing that question have not read out. Nothing authorized here speaks to it.

What this means

As of Sept. 19, 2026, the honest answer to “is there a generic Ozempic yet?” depends on where you are and what you mean by it. In Canada, yes, and it has existed since April 28, 2026, when Dr. Reddy’s became the first generic semaglutide authorized by Health Canada — Apotex, Aspen and now Sandoz have followed, and the first two are already on the market. This decision says what is authorized in Canada and nothing about what is authorized anywhere else — for another country, check that country’s medicines regulator. And in Canada, every generic semaglutide authorization that exists covers type 2 diabetes, not obesity; the one generic Wegovy product in Canada, Sevmia, is a separate authorization for chronic weight management. Sandoz’s addition raises the number of authorized suppliers of a generic Ozempic to five. It does not create the generic market, it does not lower a price today, and it does not make a weight-loss generic available.

Frequently asked questions

Is there a generic Ozempic yet?

In Canada, yes: a generic semaglutide has been authorized here since April 28, 2026, and Sandoz’s is the newest of five, announced on Sept. 18, 2026. Health Canada’s Notice of Compliance for it is dated Sept. 16, 2026. All five are copies of Ozempic, a type 2 diabetes medicine, so none is a weight-loss product, and the Sandoz authorization carries no launch date and no price. The company says it is preparing for commercialization and expects no material contribution this year, so nothing announced here makes Ozempic cheaper in Canada today. This decision says what is authorized in Canada and nothing about what is authorized anywhere else — for another country, check that country’s medicines regulator.

---

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.